Retinopathy of Prematurity (ROP) Clinical Trial
— FIREFLEYEOfficial title:
Open-label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP)
Verified date | May 2022 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.
Status | Completed |
Enrollment | 113 |
Est. completion date | February 12, 2021 |
Est. primary completion date | February 12, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 32 Weeks |
Eligibility | Inclusion Criteria: - Gestational age at birth = 32 weeks or birth weight = 1500 g - Subjects with treatment-naïve ROP classified according to the International Classification for ROP in at least one eye as: - Zone I Stage 1 plus, or 2 plus, or 3 non-plus or 3 plus, or - Zone II Stage 2 plus or 3 plus, or - Aggressive posterior retinopathy of prematurity (AP-ROP) - Weight at baseline (day of treatment) = 800 g - Signed informed consent from parent(s)/legally authorized representative(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: - Known or suspected chromosomal abnormality, genetic disorder or syndrome - Previous exposure to any IVT or systemic anti-vascular endothelial growth factor (VEGF) agent, including maternal exposure during pregnancy and/or during breastfeeding - Clinically significant neurological disease (eg, intraventricular hemorrhage grade 3 or higher, periventricular leukomalacia, congenital brain lesions significantly impairing optic nerve function, severe hydrocephalus with significantly increased intracranial pressure) - Pediatric conditions rendering the infant ineligible for study intervention at baseline or for repeated blood draws as evaluated by a NICU specialist and a study ophthalmologist - Presence of active ocular infection within 5 days of the first treatment - Advanced stages of ROP with partial or complete retinal detachment (ROP Stages 4 and 5) - ROP involving only Zone III - Ocular abnormalities that may interfere with the administration of study intervention or assessment of the study primary endpoint - Postnatal treatment with oral or intravenous corticosteroids at an equivalent dose of prednisone = 1 mg/kg/day for > 2 weeks within 14 days of the first study intervention - Previous surgical or nonsurgical treatment for ROP (IVT anti-VEGF injection, ablative laser therapy, cryotherapy, and vitrectomy) - Participation of the subject or the mother in other clinical trials requiring administration of investigational treatments (other than vitamins and minerals) at the time of screening, or within 30 days or 5 half-lives of administration of the previous study drug, whichever is longer |
Country | Name | City | State |
---|---|---|---|
Argentina | Many Locations | Multiple Locations | |
Argentina | Hospital Público Descentralizado "Dr. Guillermo Rawson" | San Juan | |
Austria | Kepler Universitätsklinikum Campus III | Linz | |
Austria | Many Locations | Multiple Locations | |
Belgium | AZ St-Jan Brugge Oostende AV | Brugge | |
Belgium | Many Locations | Multiple Locations | |
Brazil | Hospital das Clínicas de Botucatu - UNESP Botucatu | Botucatu | Sao Paulo |
Brazil | Many Locations | Multiple Locations | |
Brazil | Unifesp/Epm | Sao Paulo | |
Bulgaria | Many Locations | Multiple Locations | |
Bulgaria | UMHAT Sveti Georgi | Plovdiv | |
Bulgaria | Acibadem City Clinic Multiprofile Hospital for Active Treatm | Sofia | |
Bulgaria | II SOGHAT Sheinovo | Sofia | |
Bulgaria | SHOGAT Prof Dimitar Stamatov | Varna | |
Czechia | Many Locations | Multiple Locations | |
Czechia | Fakultni nemocnice Ostrava | Ostrava | |
Czechia | Vseobecna fakultni nemocnice v Praze | Praha 2 | |
Greece | P & A KYRIAKOU Children's Hospital | Athens | |
Greece | University General Hospital of Ioannina | Ioannina | |
Greece | Many Locations | Multiple Locations | |
Greece | Papageorgiou General Hospital of Thessaloniki | Thessaloniki | |
Hong Kong | Queen Mary Hospital | Hong Kong | |
Hong Kong | Many Locations | Multiple Locations | |
Hungary | EKBC, Uj Szent Janos Korhaz es Szakrendelo | Budapest | |
Hungary | Many Locations | Multiple Locations | |
Israel | Many Locations | Multiple Locations | |
Israel | Kaplan Medical Center | Rehovot | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano | Lombardia |
Italy | Many Locations | Multiple Locations | |
Italy | A.O. di Perugia | Perugia | Umbria |
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma | Lazio |
Italy | IRCCS Ospedale Pediatrico Bambino Gesù | Roma | Lazio |
Japan | Tokyo Metropolitan Children's Medical Center | Fuchu | Tokyo |
Japan | Fukuoka University Hospital | Fukuoka | |
Japan | Kyushu University Hospital | Fukuoka | |
Japan | Fukushima Medical University Hospital | Fukushima | |
Japan | University of Occupational and Environmental Health | Kitakyushu | Fukuoka |
Japan | Kurume University Hospital | Kurume | Fukuoka |
Japan | Many Locations | Multiple Locations | |
Japan | Saitama Children's Medical Center | Saitama | |
Japan | Okinawa Prefectural Nanbu Medical Center and Children's MC | Shimajiri-gun | Okinawa |
Japan | Showa University Hospital | Shinagawa | Tokyo |
Japan | Tokyo Metropolitan Bokutoh Hospital | Sumida-ku | Tokyo |
Japan | Tokyo Metropolitan Ohtsuka Hospital | Toshima-ku | Tokyo |
Korea, Republic of | Soon Chun Hyang University Cheonan Hospital | Cheonan-si | Chungcheongnamdo |
Korea, Republic of | Many Locations | Multiple Locations | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Malaysia | Hospital Kuala Lumpur | Kuala Lumpur | |
Malaysia | Many Locations | Multiple Locations | |
Netherlands | Many Locations | Multiple Locations | |
Netherlands | Maxima Medisch Centrum, locatie Veldhoven | Veldhoven | |
Poland | Many Locations | Multiple Locations | |
Poland | Ginekologiczno-Polozniczy SK UM im. K. Marcinkowskiego | Poznan | |
Portugal | Hospital Prof. Dr. Fernando Fonseca | Amadora | Lisboa |
Portugal | CHLO - Hospital Sao Francisco Xavier | Lisboa | |
Portugal | Many Locations | Multiple Locations | |
Romania | Clinical Emergency County Hospital | Cluj-Napoca | Cluj |
Romania | Spitalul Clinic de Obstretica si Ginecologie "Cuza Voda" | Iasi | |
Romania | Many Locations | Multiple Locations | |
Russian Federation | FSAI NMRC IRTC "Eye Microsurgery", Kaluga's Branch | Kaluga | |
Russian Federation | FGBUZ "NPC of special children care n.a. Voino-Yaseneckogo" | Moscow | |
Russian Federation | Russian National Scientific Medical University | Moscow | |
Russian Federation | Many Locations | Multiple Locations | |
Russian Federation | City Children Hospital ¿1 | Saint-Petersburg | |
Russian Federation | Pediatric Medical University | Saint-Petersburg | |
Singapore | Many Locations | Multiple Locations | |
Singapore | KK Women's and Children's Hospital | Singapore | |
Slovakia | Narodny ustav detskych chorob | Bratislava | |
Slovakia | Many Locations | Multiple Locations | |
Spain | Hospital Universitario "La Paz" | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Regional de Málaga | Málaga | |
Spain | Many Locations | Multiple Locations | |
Sweden | Sahlgrenska Universitetssjukhuset | Göteborg | |
Sweden | Many Locations | Multiple Locations | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | Many Locations | Multiple Locations | |
Taiwan | Mackay Memorial Hospital | Taipei | |
Turkey | S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi | Adana | |
Turkey | Baskent Universitesi Tip Fakultesi Hastanesi | Ankara | |
Turkey | Gazi Universitesi Tip Fakultesi | Ankara | |
Turkey | Hacettepe Universitesi Tip Fakultesi | Ankara | |
Turkey | Saglik Bilimleri Universitesi Antalya EA Hastanesi | Antalya | |
Turkey | Eskisehir Osmangazi Universitesi Tip Fakultesi | Eskisehir | |
Turkey | Many Locations | Multiple Locations | |
Ukraine | Many Locations | Multiple Locations | |
Ukraine | MI"Odesa Regional Children's Clinical Hospital" | Odesa | |
United Kingdom | Birmingham Womens Hospital | Birmingham | |
United Kingdom | Many Locations | Multiple Locations |
Lead Sponsor | Collaborator |
---|---|
Bayer | Regeneron Pharmaceuticals |
Argentina, Austria, Belgium, Brazil, Bulgaria, Czechia, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes | Active ROP was defined as ROP requiring treatment. Unfavorable structural outcomes included retinal detachment, macular dragging, macular fold, or retrolental opacity. | At 24 weeks after starting study treatment | |
Secondary | Proportion of Participants Requiring Intervention With a Second Treatment Modality | A second treatment modality for ROP was either rescue treatment or any other surgical or nonsurgical treatment for ROP (e.g. IVT anti-VEGF injection, ablative laser therapy, cryotherapy, or vitrectomy) captured as concomitant medication or surgery after study start. | From baseline (treatment) up to week 24. | |
Secondary | Proportion of Participants With Recurrence of ROP | Participants with recurrence of ROP were defined as subjects requiring re-treatment or rescue treatment after in the past the absence of treatment-requiring active ROP had been confirmed by the investigator. | From baseline (treatment) up to week 24. | |
Secondary | Exploration of ROP Activity Scale Proposed by the International Neonatal Consortium | Eyes were evaluated for change in ROP activity scale proposed by the International Neonatal Consortium (2018). ROP Activity Scale value range is from 0 to 22. Value 0 to 7 are considered mild, 8 to 12 are moderate, and 13 to 22 are severe. Value 0 means the best and value 22 means the worst. Eyes evaluation was done at baseline and each visit. | From baseline (treatment) up to week 24. | |
Secondary | Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) | A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular TEAEs in treated eyes only were reported | From baseline (treatment) up to week 24 | |
Secondary | Percentage of Participants With Ocular Serious Adverse Events (SAEs) | Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular SAEs in treated eyes only were reported. | From baseline (treatment) up to week 24 | |
Secondary | Percentage of Participants With Systemic TEAEs | A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic TEAEs only were reported. | From baseline (treatment) up to week 24 | |
Secondary | Percentage of Participants With Systemic SAEs | Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic SAEs only were reported. | From baseline (treatment) up to week 24 | |
Secondary | Concentrations of Free Aflibercept in Plasma | Blood samples for determination of aflibercept concentrations in plasma were collected in the aflibercept 0.4 mg arm at Day 1 (within 24 hours after injection), and at weeks 2 and 4, and if feasible also at weeks 8, 12 and 24. Statistics for week 8, 12, 24 not calculated as > 1/3 of the concentrations were below the lower limit of quantification. Free Aflibercept Concentrations in Plasma were only measured in the Aflibercept 0.4 mg treatment arm. | From Day 1 up to week 24. | |
Secondary | Number of Participants With Anti-drug Antibodies (ADA) | Immunogenicity was characterized by anti-drug antibody (ADA) responses in patients in the aflibercept 0.4 mg arm. Serum samples were taken at baseline prior to the injection and at 12 weeks after injection. ADA titers were summarized for 3 categories: Low (titer <1,000); Moderate (1,000 = titer = 10,000); High (titer >10,000). ADA in serum were only measured in the Aflibercept 0.4 mg treatment arm. | Baseline (treatment) and 12 weeks after aflibercept injection | |
Secondary | Number of Participants With Potential Neutralizing Antibodies (NAb) | NAb status was evaluated for the samples that were positive in the ADA assay and had sufficient volume to analyze. NAb were only measured in participants with positive ADA in the Aflibercept 0.4 mg treatment arm | At 12 weeks after aflibercept injection | |
Secondary | Number of Aflibercept Administrations | Total number of injections in both eyes. | From baseline (treatment) up to week 24. | |
Secondary | Number of Laser Treatments | Total number of laser treatment in both eyes. If multiple sessions of laser treatment were necessary within 1 week from baseline, they were counted as a single treatment. | From baseline (treatment) up to week 24. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Recruiting |
NCT03253263 -
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
|
Phase 2 | |
Completed |
NCT02386839 -
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
|
Phase 2 | |
Withdrawn |
NCT01470430 -
VEGF In Systemic Circulation Of ROP-infants
|
N/A | |
Completed |
NCT01054027 -
Study on Effective Mydriasis in Premature Infants
|
N/A | |
Active, not recruiting |
NCT04015180 -
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
|
Phase 3 | |
Completed |
NCT01096784 -
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
|
Phase 2 | |
Completed |
NCT02640664 -
Rainbow Extension Study
|
Phase 3 | |
Completed |
NCT02134457 -
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
|
Phase 2 | |
Terminated |
NCT01954082 -
Inositol to Reduce Retinopathy of Prematurity
|
Phase 3 |